[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Epiliquid Holding, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100604345",false,"NCT07148310","Hepatocellular Carcinoma Identification Using Delta-HLD","Proof-of-Concept Case-Control Study for Hepatocellular Carcinoma Identification Using Delta-HLD Technology (HIDE)","HIDE","Inclusion Criteria:\n\n* Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls)\n* Willing and able to provide informed consent\n* Available paired plasma and liver tissue sample\n\nExclusion Criteria:\n\n* Other active cancers\n* Prior liver transplantation\n* Known hereditary cancer syndromes\n* Recent chemotherapy or antiviral treatment (\\\u003C3 months)","ALL","18 Years","75 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.",[25],"Hepato Cellular Carcinoma (HCC)",[27,28,29,30,31,32,33],"Hepatocellular carcinoma","Epigenetics","Liquid Biopsy","cfDNA","Biomarker","Methylation","PCR","RECRUITING","2025-09-08",{"date":37,"type":38},"2025-09-09","ACTUAL",{"date":40,"type":38},"2023-05-18",{"date":42,"type":21},"2026-12",{"name":44,"class":45},"Epiliquid Holding, Inc","INDUSTRY",1,{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":18,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100605926","NCT07168876","Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)","Clinical Validation Cross-sectional Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CLIMBED)","CLIMBED","Inclusion Criteria:\n\n* Men and women aged 45-75 years\n* Indication of colorectal cancer screening colonoscopy by treating physician\n\nExclusion Criteria:\n\n* First-degree family history of CRC\n* Inflammatory bowel disease (ulcerative colitis, Crohn's disease)\n* Other malignancies within 5 years\n* Known hereditary CRC syndromes (Lynch, FAP)\n* Major trauma, surgery, transfusion in past 30 days\n* Current participation in an interventional clinical trial",true,"45 Years",{"count":57,"type":21},3200,"CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.",[60],"Colorectal Cancer (CRC)",[62,28,63,30,31,64,33],"Colorectal cancer","Liquid biopsy","Methylarion","2025-09-04",{"date":67,"type":38},"2025-09-11",{"date":69,"type":38},"2024-04-04",{"date":71,"type":21},"2028-12",{"name":44,"class":45},{"id":74,"slug":4,"hasResults":10,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":10,"sex":16,"minAge":55,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":92,"locationsCount":46},"100604344","NCT07148297","Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD","Proof-of-concept Case-control Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CASCADE)","CASCADE","Inclusion Criteria:\n\n* Candidate for colonoscopy or colorectal surgery\n* Willing and able to provide informed consent\n* Able to provide blood and\u002For tissue sample before treatment or resection\n\nExclusion Criteria:\n\n* Prior history of colorectal cancer\n* Inflammatory bowel disease\n* Known hereditary cancer syndromes (e.g., Lynch, FAP)\n* Other active malignancies\n* Recent chemotherapy or immunosuppressive treatment",{"count":81,"type":21},600,"CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.",[84],"Colo-rectal Cancer",[62,28,29,30,31,32,33],"2025-08-22",{"date":88,"type":38},"2025-08-29",{"date":90,"type":38},"2021-06-30",{"date":42,"type":21},{"name":44,"class":45},""]